期刊文献+

APC基因的DNA甲基化与卵巢癌关系荟萃分析 被引量:3

A Meta-analysis of DNA-Methylated Gene APC and Ovarian Cancer
下载PDF
导出
摘要 目的:进一步探讨结肠腺瘤性息肉病基因(APC基因)的失活在卵巢癌的发生、发展中的作用。方法:搜索PubMed、EMBase、Web of Science及CNKI数据库中2000年1月1日—2014年12月31日有关APC基因甲基化与卵巢上皮癌相关的文献,纳入研究均为包含病例组及对照组的随机对照试验。纳入文献采用纽卡斯尔-渥太华量表(NOS)评价标准。使用Stata 11.0软件进行OR值、异质性及发表性偏倚的相关的统计学分析。结果:共纳入9篇文献,其中包括641例卵巢癌患者和377例对照者。总病例组与总对照组的APC基因甲基化发生率差异有统计学意义(OR=6.19,95%CI:4.08~9.41,P=0.000);卵巢癌组织与正常组织的APC基因甲基化发生率差异有统计学意义(OR=5.88,95%CI:3.66~9.45,P=0.000);卵巢癌组织与良性卵巢肿瘤组织的APC基因甲基化发生率差异有统计学意义(OR=6.99,95%CI:3.12~15.64,P=0.000)。结论:APC基因甲基化可能与卵巢癌有关。 Objective:To investigate the role of APC gene inactivation in the occurrence and development of ovarian cancer. Methods:Databases such as Pub Med, EMBase, Web of Science, and CNKI data were searched. Related literatures were published from January 1, 2000 to December 31, 2014. Only randomized controlled trials were included. The quality of the included studies were assessed by Newcastle-Ottawa Scale(NOS). Stata 11.0 software was used for statistical analysis such as OR value,heterogeneity and publication bias. Results:Nine studies, with 641 ovarian cancer patients and 377 controls were included in the Meta-analysis. Statistical results shows that the pooled odds ratio was 6.19(95% CI: 4.08-9.41, P=0.000) in the case group versus the control group under fix effects model. The pooled odds ratio was 5.88(95%CI: 3.662-9.450, P=0.000) in the cancer group versus the normal group under fix effects model. The pooled odds ratio was 6.99(95% CI: 3.12-15.64, P =0.000) in the cancer group versus the benign tumor group under fix effects model. Conclusions:This analysis suggests that APC gene methylation had an association with ovarian cancer.
作者 闫冰冰 李力
出处 《国际妇产科学杂志》 CAS 2016年第2期169-173,共5页 Journal of International Obstetrics and Gynecology
基金 教育部高校博士学科点专项基金(20124503110003) 广西科学研究与技术开发计划项目(桂科攻1140003A-34)
关键词 卵巢肿瘤 基因 APC DNA甲基化 META分析 Ovarian neoplasms Genes APC DNA methylation Meta-analysis
  • 相关文献

参考文献13

  • 1Jarrett CR,Blancato J,Cao T,et al. Human APC2 localization and allelic imbalance[J]. Cancer Res, 2001,61 (21 ) : 7978-7984.
  • 2van Noort M, Meeldijk J, van der Zee R, et al. Wnt signaling controls the phosphorylation status of beta-catenin [J]. J Biol Chem, 2002,277(20): 17901-17905.
  • 3Tam KF,Liu VW,Liu SS,et al. borderline and malignant ovarian Oneol, 2007,133(5) :331-341.
  • 4Methylation profile in benign, tumors [J]. J Cancer Res Clin A1-Shabanah OA,Hafez MM,Hassan ZK,et al. Methylation of SFRPs and APC genes in ovarian cancer infected with high risk human papillomavirus [J]. Asian Pac J Cancer Prey,2014,15 (6): 2719-2725.
  • 5Brait M,Maldonado L,Noordhuis MG,et al, Association of promoter methylation of VGF and PGP0.5 with ovarian cancer progression[J]. PLoS One,2013,8(9) :e70878.
  • 6Ho CM, Lai HC, Huang SH, et al. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma[J]. Eur J Clin Invest, 2010,40(4) : 310-318.
  • 7Wu Q,Lothe RA,Ahlquist T,et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets [J]. Mal Cancer, 2007,6 : 45.
  • 8Rathi A,Virmani AK,Schorge JO,et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women[J]. Clin Cancer Res, 2002,8 ( 11 ) : 3324-3331.
  • 9Bhagat R,Chadaga S,Premalata CS,et al. Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development [J]. Cell Oncol (Dordr),2012,35 (6) :473 - 479.
  • 10Ho CM, Huang C J, Huang CY, et al. Promoter methylation status of HIN -1 associated with outcomes of ovarian clear cell adenocarcinoma[J]. Mol Cancer, 2012,11 : 53.

同被引文献25

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部